All In Biotech

Drug Trial Radar · NCT05720117

A Study of PYX-201 in Advanced Solid Tumors

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Mar 14, 2023

Primary completion

Apr 25, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Pyxis Oncology, IncIndustry
Sponsor type
Industry
First posted
Feb 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

Conditions

  • Solid Tumor
  • Advanced Solid Tumor

Interventions

  • PYX-201Drug

    Antibody-Drug Conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose EscalationTime frame: Day 1 to Day 21
  2. Safety and Tolerability as assessed by adverse event monitoring for participants in Dose EscalationTime frame: Up to approximately 3 years
  3. Objective Response Rate (ORR) observed in participants in Dose ExpansionTime frame: Up to approximately 2 years

Locations

29 sites in 4 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • SCRI - HealthOne Denver

    Denver, Colorado · Recruiting

  • SCRI - Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • NEXT Dallas

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Institut Jules Bordet

    Brussels, Brussels Capital, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Brussels Capital, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Edegem, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Gent, Belgium · Recruiting

  • Hospital Universitari Vall d'Hebrón

    Barcelona, Barcelona, Spain · Recruiting

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, Madrid, Spain · Recruiting

  • Hospital Clínico Universitario de Valencia

    Valencia, València, Spain · Recruiting

  • University College Hospital

    London, England, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    London, England, United Kingdom · Recruiting

  • Sarah Cannon Research Institute London

    London, England, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.